Native HLA Detection Using Enzymatic Cleavage of Denatured Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting antibodies to human leukocyte antigens (HLAs) cannot distinguish between antibodies to native and denatured HLAs, leading to false positive signals and potential graft rejection in transplant recipients.
Innovation Solution
Development of compositions and methods that selectively enrich native HLAs on solid substrates, with at least 90% native and at most 10% denatured HLAs, allowing for specific detection of antibodies to native HLAs using serine proteases, lipases, or esterases to cleave denatured HLAs, followed by neutralization to maintain native HLA integrity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional substrates linked to both native and denatured HLAs are used for antibody detection, then the detection process is simple and straightforward, but the ability to distinguish between antibodies to native and denatured HLAs is limited, leading to false positive signals
Solution Approach 1:
The substrate population is segmented into distinct categories: substrates with native HLA, substrates with denatured HLA, and substrates with both. This segmentation allows the assay to differentiate between antibodies targeting native versus denatured conformational epitopes, resolving the false positive problem while maintaining manageable complexity through systematic classification
Solution Approach 2:
Different substrates are assigned different local qualities in terms of HLA conformational state. By creating substrates with specifically native HLA, specifically denatured HLA, or both, the system enables localized detection of antibody specificity, allowing precise identification of clinically relevant anti-native HLA antibodies without interference from anti-denatured HLA antibodies
2Productivity
If substrates with both native and denatured HLAs are used, then the assay can detect all HLA antibodies, but it cannot distinguish between antibodies to native and denatured HLAs, causing false positives and unnecessary donor exclusion
Solution Approach 1:
The system dynamically adapts substrate composition based on assay objectives. Different substrate formulations (native-only, denatured-only, or mixed) can be selected depending on whether the goal is to detect anti-native HLA antibodies, anti-denatured HLA antibodies, or perform comprehensive screening, thereby optimizing both productivity and reliability for specific clinical scenarios
Solution Approach 2:
The conformational state parameter of HLA on substrates is systematically varied to create distinct assay conditions. By controlling the native/denatured ratio as a key parameter, the method enables reliable differentiation of antibody specificity, improving detection reliability while maintaining high transplant matching efficiency through accurate risk assessment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate detection of antibodies to native HLAs, reducing false positives and improving transplant compatibility by distinguishing between native and denatured HLA antibodies, thereby preventing unnecessary exclusion of potential donors.
Implementation Method 1
contacting the first composition with a serine protease, lipase, esterase, or amidase under conditions wherein the serine protease, lipase, esterase, or amidase cleaves the denatured HLAs
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.